Neoadjuvant PD-1 Blockade in Resectable Lung Cancer | Zendy

Patrick M. Forde | Zendy; Jamie E. Chaft | Zendy; Kellie N. Smith | Zendy; Valsamo Anagnostou | Zendy; Tricia R. Cottrell | Zendy; Matthew D. Hellmann | Zendy; Marianna Zahurak | Zendy; Stephen C. Yang | Zendy; David R. Jones | Zendy; Stephen Broderick | Zendy; Richard J. Battafarano | Zendy; Moises J. Velez | Zendy; Natasha Rekhtman | Zendy; Zachary T. Olah | Zendy; Jarushka Naidoo | Zendy; Kristen A. Marrone | Zendy; Franco Verde | Zendy; Haidan Guo | Zendy; Jiajia Zhang | Zendy; Justina X. Caushi | Zendy; Hok Yee Chan | Zendy; John-William Sidhom | Zendy; Robert B. Scharpf | Zendy; James R. White | Zendy; Edward Gabrielson | Zendy; Hao Wang | Zendy; Gary L. Rosner | Zendy; Valerie W. Rusch | Zendy; Jedd D. Wolchok | Zendy; Taha Merghoub | Zendy; Janis M. Taube | Zendy; Victor E. Velculescu | Zendy; Suzanne L. Topalian | Zendy; Julie R. Brahmer | Zendy; Drew M. Pardoll | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Author(s) -

Patrick M. Forde,

Jamie E. Chaft,

Kellie N. Smith,

Valsamo Anagnostou,

Tricia R. Cottrell,

Matthew D. Hellmann,

Marianna Zahurak,

Stephen C. Yang,

David R. Jones,

Stephen Broderick,

Richard J. Battafarano,

Moises J. Velez,

Natasha Rekhtman,

Zachary T. Olah,

Jarushka Naidoo,

Kristen A. Marrone,

Franco Verde,

Haidan Guo,

Jiajia Zhang,

Justina X. Caushi,

Hok Yee Chan,

John-William Sidhom,

Robert B. Scharpf,

James R. White,

Edward Gabrielson,

Hao Wang,

Gary L. Rosner,

Valerie W. Rusch,

Jedd D. Wolchok,

Taha Merghoub,

Janis M. Taube,

Victor E. Velculescu,

Suzanne L. Topalian,

Julie R. Brahmer,

Drew M. Pardoll

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1716078

Subject(s) - blockade , medicine , lung cancer , neoadjuvant therapy , oncology , cancer , receptor , breast cancer

Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research